More importantly, inhibiting SREBP-1 through pharmacological intervention re-sensitized BRAF-mutant melanoma cells to BRAF inhibitor therapies, demonstrating that combinational SREBP-1 and BRAF inhibitors are more effective in targeting drug-resistant cells [85]. The gene discussed is SREBF1; the disease is melanoma.